Smith & Nephew will acquire Integra LifeSciences’ orthopedics business in a 240 million dollar cash deal set to close at the end of 2020. The focus will be on growing the upper and lower extremity markets, adding products covering shoulder replacements and reconstructions of the hand, wrist, elbow, ankle, and foot. Through the acquisition, Smith & Nephew will also gain access to Integra’s next-generation shoulder replacement system, which is scheduled for a commercial launch in 2022. Additionally, it will bring a strong sales force and distributors to the United States, Canada, and Europe.
About 300 employees are expected to move from Integra, which is based out of Lyon, France, and Austin, Texas. Although sales decreased due to COVID-19 and the postponement of elective surgeries (down 48.6 percent in the second quarter of 2020 versus the same time in 2019), Smith & Nephew anticipates the business to deliver double-digit revenue growth in 2021 and 2022.
For Integra, the acquisition will allow the company to focus its efforts on developments in neurosurgery, surgical instrumentation, and regenerative medicine.
Further Reading:
Tracy Everhart
Tracy Everhart is the Editor for Drug Law Journal. A highly-trained and certified medical professional, Tracy is also an accomplished medical writer. After spending years on the front lines of the medical profession, Tracy now devotes her expertise and skills to researching and reporting on new drugs and devices that enter the market, as well as their side-effects and the real-life stories involved. Prior to joining Drug Law Journal, Tracy wrote for benchmark online healthcare resources focused on families and, in particular, women’s health issues. Tracy holds post-graduate degrees from both the American College of Healthcare Sciences and the Yale School of Nursing. She is also a graduate of both Hampshire College, where she studied microbiology and the University of South Carolina school of nursing.
